HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis

Kinase Inhibitor ◽

Potential Drug ◽

Monocyte Activation ◽

The Bruton’s tyrosine kinase inhibitor acalabrutinib protects from anaphylaxis in a humanized mouse model

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2018.12.438 ◽

2019 ◽

Vol 143 (2) ◽

pp. AB144 ◽

Cited By ~ 1

Author(s):

Melanie C. Dispenza ◽

Rebecca A. Krier-Burris ◽

Bruce S. Bochner

Keyword(s):

Mouse Model ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Humanized Mouse ◽

Humanized Mouse Model ◽

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care

PLoS ONE ◽

10.1371/journal.pone.0181782 ◽

2017 ◽

Vol 12 (7) ◽

pp. e0181782 ◽

Cited By ~ 16

Author(s):

Kathleen M. Gillooly ◽

Claudine Pulicicchio ◽

Mark A. Pattoli ◽

Lihong Cheng ◽

Stacey Skala ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Standard Of Care ◽

Experimental Models ◽

Abstract 4634: Population pharmacokinetic model of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the treatment of B-cell malignancies

10.1158/1538-7445.am2014-4634 ◽

2014 ◽

Author(s):

Eleonora Marostica ◽

Juthamas Sukbuntherng ◽

David Loury ◽

Jan D. Jong ◽

Xavier Woot de Trixhie ◽

...

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Population Pharmacokinetic Model ◽

Pharmacokinetic Model ◽

Kinase Inhibitor ◽

Population Pharmacokinetic ◽

B Cell Malignancies ◽

Phase I, first-in-human trial of Bruton’s tyrosine kinase inhibitor M7583 in patients with B-cell malignancies

Leukemia & Lymphoma ◽

10.1080/10428194.2021.1913139 ◽

2021 ◽

pp. 1-8

Author(s):

Wojciech Jurczak ◽

Simon Rule ◽

William Townsend ◽

David Tucker ◽

Barbara Sarholz ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

B Cell ◽

Kinase Inhibitor ◽

B Cell Malignancies ◽

Human Trial

PS1148 PRELIMINARY RESULTS OF A PHASE 1B/2 DOSE-ESCALATION AND COHORT-EXPANSION STUDY OF THE NONCOVALENT, REVERSIBLE BRUTON'S TYROSINE KINASE INHIBITOR (BTKI), VECABRUTINIB, IN B-CELL MALIGNANCIES

HemaSphere ◽

10.1097/01.hs9.0000562876.57990.65 ◽

2019 ◽

Vol 3 (S1) ◽

pp. 520 ◽

Cited By ~ 3

Author(s):

J.N. Allan ◽

K. Patel ◽

A.R. Mato ◽

W.G. Wierda ◽

J. Pinilla-Ibarz ◽

...

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Dose Escalation ◽

Kinase Inhibitor ◽

B Cell Malignancies ◽

Preliminary Results ◽

Phase 1B

Current Status of Bruton’s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies

Drugs & Aging ◽

10.1007/s40266-017-0468-4 ◽

2017 ◽

Vol 34 (7) ◽

pp. 509-527 ◽

Cited By ~ 23

Author(s):

Andrew Aw ◽

Jennifer R. Brown

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Kinase Inhibitor ◽

Current Status ◽

B Cell Malignancies ◽

Inhibitor Development

Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies

Annals of the New York Academy of Sciences ◽

10.1111/nyas.12878 ◽

2015 ◽

Vol 1358 (1) ◽

pp. 82-94 ◽

Cited By ~ 21

Author(s):

Urte Gayko ◽

Mann Fung ◽

Fong Clow ◽

Steven Sun ◽

Elizabeth Faust ◽

...

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Kinase Inhibitor ◽

B Cell Malignancies ◽

Abstract 4543: High-throughput combination screening identifies novel drug-drug pairings for a Bruton's tyrosine kinase inhibitor against the ABC subtype of diffuse large B-cell lymphomas.

10.1158/1538-7445.am2013-4543 ◽

2013 ◽

Author(s):

Lesley A. Mathews ◽

Rajarshi Guha ◽

Paul Shinn ◽

Ryan M. Young ◽

Kian-Huat Lim ◽

...

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

High Throughput ◽

Kinase Inhibitor ◽

B Cell Lymphomas ◽

Novel Drug ◽

Large B Cell

Discovery of a highly potent and selective Bruton’s tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma

Signal Transduction and Targeted Therapy ◽

10.1038/s41392-020-00309-1 ◽

2020 ◽

Vol 5 (1) ◽

Author(s):

Juan Liu ◽

Qianmao Liang ◽

Aoli Wang ◽

Fengming Zou ◽

Ziping Qi ◽

...

Keyword(s):

Tyrosine Kinase ◽

B Cell ◽

Hodgkin Lymphoma ◽

Kinase Inhibitor ◽

Non Hodgkin Lymphoma

Phase I/II, first in human trial with M7583, a Bruton’s tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies

Annals of Oncology ◽

10.1093/annonc/mdy286.010 ◽

2018 ◽

Vol 29 ◽

pp. viii362-viii363 ◽

Cited By ~ 1

Author(s):

W. Jurczak ◽

S. Rule ◽

W. Townsend ◽

D. Tucker ◽

B. Sarholz ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

B Cell ◽

Kinase Inhibitor ◽

B Cell Malignancies ◽

Human Trial